BR112021016149A2 - Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met - Google Patents
Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met Download PDFInfo
- Publication number
- BR112021016149A2 BR112021016149A2 BR112021016149-0A BR112021016149A BR112021016149A2 BR 112021016149 A2 BR112021016149 A2 BR 112021016149A2 BR 112021016149 A BR112021016149 A BR 112021016149A BR 112021016149 A2 BR112021016149 A2 BR 112021016149A2
- Authority
- BR
- Brazil
- Prior art keywords
- egfr
- cancer
- met
- seq
- jnj
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810716P | 2019-02-26 | 2019-02-26 | |
| US62/810,716 | 2019-02-26 | ||
| US201962930190P | 2019-11-04 | 2019-11-04 | |
| US62/930,190 | 2019-11-04 | ||
| PCT/IB2020/051559 WO2020174370A2 (en) | 2019-02-26 | 2020-02-24 | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021016149A2 true BR112021016149A2 (pt) | 2021-10-13 |
Family
ID=72142314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021016149-0A BR112021016149A2 (pt) | 2019-02-26 | 2020-02-24 | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11459391B2 (https=) |
| EP (1) | EP3931224A4 (https=) |
| JP (3) | JP7703448B2 (https=) |
| KR (1) | KR20210132117A (https=) |
| CN (1) | CN113840842A (https=) |
| AU (1) | AU2020229467A1 (https=) |
| BR (1) | BR112021016149A2 (https=) |
| CA (1) | CA3131654A1 (https=) |
| IL (1) | IL285718A (https=) |
| JO (1) | JOP20210233A1 (https=) |
| MA (1) | MA55089A (https=) |
| MX (1) | MX2021010265A (https=) |
| NZ (1) | NZ778579A (https=) |
| PH (1) | PH12021552030A1 (https=) |
| SG (1) | SG11202108311RA (https=) |
| WO (1) | WO2020174370A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| SG11202111120VA (en) * | 2019-04-17 | 2021-11-29 | Univ Texas | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations |
| WO2020230091A1 (en) * | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| AU2020275272A1 (en) * | 2019-05-14 | 2021-12-02 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| PH12022552076A1 (en) | 2020-02-12 | 2023-11-29 | Janssen Biotech Inc | TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS |
| IL300854A (en) | 2020-08-25 | 2023-04-01 | Janssen Biotech Inc | Treatment of non-small cell lung cancer with EGFR mutations |
| IL305700A (en) * | 2021-03-09 | 2023-11-01 | Janssen Biotech Inc | Treatment of cancers lacking EFGR-activating mutations |
| TW202317635A (zh) * | 2021-07-14 | 2023-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｈｇｆｒ和ｅｇｆｒ的抗原結合分子及其醫藥用途 |
| KR20240051145A (ko) * | 2021-07-29 | 2024-04-19 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Kras 돌연변이 암의 치료를 위한 방법 및 조성물 |
| KR102793991B1 (ko) | 2021-10-06 | 2025-04-09 | 주식회사 엘지에너지솔루션 | 태양광 시스템과 연계하는 에너지 저장 시스템 및 에너지 저장 시스템의 제어 방법 |
| US20230183360A1 (en) * | 2021-12-09 | 2023-06-15 | Janssen Biotech, Inc. | Use of Amivantamab to Treat Colorectal Cancer |
| CN120882752A (zh) * | 2023-03-13 | 2025-10-31 | 詹森生物科技公司 | 双特异性抗EGFR/c-Met抗体和抗PD-1抗体的组合疗法 |
| KR20260005269A (ko) * | 2023-04-24 | 2026-01-09 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | c-Met를 표적으로 하는 다중 특이성 항체 |
| TW202519556A (zh) * | 2023-09-28 | 2025-05-16 | 大陸商上海翰森生物醫藥科技有限公司 | 雙特異性抗體在製備治療癌症的藥物中的用途 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| CN101501211A (zh) | 2004-03-31 | 2009-08-05 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
| EP1766068A4 (en) | 2004-06-04 | 2010-03-03 | Genentech Inc | EGFR Mutations |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| CN101193905B (zh) | 2005-02-11 | 2014-06-25 | 纪念斯隆-凯特林癌症中心 | 用于检测抗药egfr突变体的方法和组合物 |
| MX2007009963A (es) | 2005-02-24 | 2007-09-26 | Amgen Inc | Mutaciones del receptor del factor de crecimiento epidermico. |
| WO2006104911A2 (en) | 2005-03-25 | 2006-10-05 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CA2683559C (en) | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US7892770B2 (en) | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| EP2260056A1 (en) * | 2008-03-06 | 2010-12-15 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US8962808B2 (en) | 2010-05-05 | 2015-02-24 | The Research Foundation For The State University Of New York | EGFR-related polypeptides and methods of use |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| US10570211B2 (en) | 2011-01-24 | 2020-02-25 | Gilead Sciences, Inc. | Antibodies selective for cells presenting EGFR at high density |
| US9683052B2 (en) | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| CN107266577B (zh) | 2011-10-11 | 2022-09-13 | 弗·哈夫曼-拉罗切有限公司 | 双特异性抗体的改进的组装 |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| US20170275367A1 (en) * | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| CN113201073A (zh) * | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| WO2015043614A1 (en) * | 2013-09-26 | 2015-04-02 | Biontech Ag | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| WO2015188777A1 (en) | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CA2967379A1 (en) | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| US10507210B2 (en) * | 2014-12-03 | 2019-12-17 | Auckland Uniservices Limited | Kinase inhibitor prodrug for the treatment of cancer |
| US12595297B2 (en) * | 2015-05-12 | 2026-04-07 | In3Bio Ltd. | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors |
| CA3002957A1 (en) | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| JP2018535242A (ja) | 2015-11-30 | 2018-11-29 | メディミューン，エルエルシー | 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比 |
| EP3453392B1 (en) | 2016-05-17 | 2025-10-22 | Japanese Foundation For Cancer Research | Therapeutic agent for lung cancer that has acquired egfr-tki resistance |
| US11649291B2 (en) | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
| GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| HUE054571T2 (hu) | 2016-09-14 | 2021-09-28 | Merck Patent Gmbh | Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| WO2018152634A1 (en) | 2017-02-22 | 2018-08-30 | University Of Saskatchewan | Egfr-binding agents and uses thereof |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| CA3110658A1 (en) | 2018-09-04 | 2020-03-19 | Rain Therapeutics Inc. | Compounds, compositions and methods for treating or preventing her-driven cancers |
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| EP3946293A4 (en) | 2019-03-29 | 2023-05-03 | Board of Regents, The University of Texas System | COMPOUNDS WITH ANTITUMORIC ACTIVITIES AGAINST CANCER CELLS WITH EGFR OR HER2 EXON 20 INSERTATIONS |
| SG11202111120VA (en) | 2019-04-17 | 2021-11-29 | Univ Texas | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations |
| EP3955928A4 (en) | 2019-04-17 | 2023-05-31 | Board of Regents, The University of Texas System | COMPOUNDS HAVING ANTITUMORIC ACTIVITY AGAINST CANCER CELLS WITH TYROSINE KINAS INHIBITOR-RESISTANT EGFR MUTATIONS |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| TW202309094A (zh) * | 2021-05-18 | 2023-03-01 | 美商健生生物科技公司 | 用於識別癌症患者以進行組合治療之方法 |
-
2020
- 2020-02-24 SG SG11202108311RA patent/SG11202108311RA/en unknown
- 2020-02-24 NZ NZ778579A patent/NZ778579A/en unknown
- 2020-02-24 KR KR1020217030301A patent/KR20210132117A/ko active Pending
- 2020-02-24 JP JP2021549746A patent/JP7703448B2/ja active Active
- 2020-02-24 CN CN202080017112.1A patent/CN113840842A/zh active Pending
- 2020-02-24 MX MX2021010265A patent/MX2021010265A/es unknown
- 2020-02-24 AU AU2020229467A patent/AU2020229467A1/en active Pending
- 2020-02-24 PH PH1/2021/552030A patent/PH12021552030A1/en unknown
- 2020-02-24 CA CA3131654A patent/CA3131654A1/en active Pending
- 2020-02-24 BR BR112021016149-0A patent/BR112021016149A2/pt unknown
- 2020-02-24 US US16/798,662 patent/US11459391B2/en active Active
- 2020-02-24 EP EP20763439.5A patent/EP3931224A4/en active Pending
- 2020-02-24 MA MA055089A patent/MA55089A/fr unknown
- 2020-02-24 WO PCT/IB2020/051559 patent/WO2020174370A2/en not_active Ceased
-
2021
- 2021-08-18 IL IL285718A patent/IL285718A/en unknown
- 2021-08-23 JO JOP/2021/0233A patent/JOP20210233A1/ar unknown
-
2022
- 2022-08-03 US US17/817,295 patent/US12215161B2/en active Active
-
2024
- 2024-07-04 JP JP2024108371A patent/JP2024153659A/ja active Pending
- 2024-12-20 US US18/990,769 patent/US20250236675A1/en active Pending
-
2025
- 2025-01-30 JP JP2025014414A patent/JP2025084739A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12215161B2 (en) | 2025-02-04 |
| EP3931224A4 (en) | 2023-03-01 |
| JP2022521610A (ja) | 2022-04-11 |
| IL285718A (en) | 2021-10-31 |
| CN113840842A (zh) | 2021-12-24 |
| JOP20210233A1 (ar) | 2023-01-30 |
| WO2020174370A3 (en) | 2020-12-03 |
| AU2020229467A1 (en) | 2021-08-12 |
| JP2025084739A (ja) | 2025-06-03 |
| US20200270351A1 (en) | 2020-08-27 |
| US20250236675A1 (en) | 2025-07-24 |
| SG11202108311RA (en) | 2021-09-29 |
| MX2021010265A (es) | 2021-09-23 |
| WO2020174370A2 (en) | 2020-09-03 |
| JP7703448B2 (ja) | 2025-07-07 |
| EP3931224A2 (en) | 2022-01-05 |
| JP2024153659A (ja) | 2024-10-29 |
| MA55089A (fr) | 2022-01-05 |
| US20230130600A1 (en) | 2023-04-27 |
| PH12021552030A1 (en) | 2022-08-15 |
| US11459391B2 (en) | 2022-10-04 |
| CA3131654A1 (en) | 2020-09-03 |
| KR20210132117A (ko) | 2021-11-03 |
| NZ778579A (en) | 2026-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12215161B2 (en) | Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies | |
| JP7116113B2 (ja) | がんを治療するためのｐｄ－１／ｐｄ－ｌ１阻害剤 | |
| US12528869B2 (en) | Treatment of non-small cell lung cancer with EGFR mutations | |
| EP3938396A1 (en) | Anti-icos antibodies for the treatment of cancer | |
| CN110636861A (zh) | 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法 | |
| KR20260013482A (ko) | 비-소세포 폐암(nsclc)의 치료 방법 | |
| CA3213216A1 (en) | Tgf-beta inhibitors and use thereof | |
| US20220298248A1 (en) | Treatment of Cancers Lacking EGFR- Activating Mutations | |
| JP2023553257A (ja) | がんの組み合わせ治療 | |
| US20240228634A1 (en) | Treatment of Cancers Lacking EGFR- Activating Mutations | |
| US20260048065A1 (en) | Methods for treatment of non-small cell lung cancer (nsclc) | |
| EA050561B1 (ru) | Лечение немелкоклеточного рака легкого с мутациями egfr | |
| TW202529808A (zh) | Ｅｇｆｒ外顯子２０插入突變之晚期非小細胞肺癌中的第一線治療 | |
| WO2026042017A1 (en) | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) | |
| CA3222287A1 (en) | First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer | |
| EA050641B1 (ru) | Лечение раковых заболеваний без активирующих мутаций egfr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |